Robert Busch, MD

Articles by Robert Busch, MD

Protecting Cardiorenal Function In Diabetic Kidney Disease

ByDhiren Patel, PharmD, CECES, BC-ADM,Robert Busch, MD,Stephen Brunton, MD, FAAFP, CDCES

November 6th 2023

Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

Protecting Cardiorenal Function in Diabetic Kidney Disease

ByDhiren Patel, PharmD, CECES, BC-ADM,Robert Busch, MD,Stephen Brunton, MD, FAAFP, CDCES

October 26th 2023

Experts discuss the intricate relationship between diabetes, kidney disease, and cardiovascular function and explore the evolving landscape of therapies with cardiorenal benefits.

Mitigating Cardiovascular Risk In Obesity

ByDhiren Patel, PharmD, CECES, BC-ADM,Robert Busch, MD,Fatima Cody Stanford, MD, MPH, MPA

October 23rd 2023

Mitigating Cardiovascular Risk in Obesity

ByDhiren Patel, PharmD, CECES, BC-ADM,Robert Busch, MD,Fatima Cody Stanford, MD, MPH, MPA

October 13th 2023

Untapped Potentials - Exploring Overlooked Therapies for Type 2 Diabetes

ByDhiren Patel, PharmD, CECES, BC-ADM,Robert Busch, MD,Tara Dall, MD, FNLA

October 9th 2023

In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.

Untapped Potentials: Exploring Overlooked Therapies for Type 2 Diabetes

ByDhiren Patel, PharmD, CECES, BC-ADM,Robert Busch, MD,Tara Dall, MD, FNLA

September 29th 2023

In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.

Exploring SGLT2 Inhibitor Benefits in Chronic Kidney Disease

ByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES,Robert Busch, MD

June 23rd 2023

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.

Exploring the Benefits of SGLT2 Inhibitors in Chronic Kidney Disease

ByDiana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES,Robert Busch, MD

June 23rd 2023

Strategies to Improve Screening and Diagnosis of T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 24th 2023

Drs Robert Busch, Robin S. Goland, Kimberly Simmons, and Teresa Quattrin discuss strategies to facilitate screening of type 1 diabetes and improve management of disease.

Managing T1D Comorbidities

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 24th 2023

Experts in endocrinology share their approach to managing type 1 diabetes along with related health conditions.

Investigational Therapies for the Management of T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 17th 2023

Teresa Quattrin, MD, reviews emerging clinical trial data on novel therapies to delay the progression of type 1 diabetes.

Patient Monitoring After Teplizumab Therapy in T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 17th 2023

Kimberly Simmons, MD, MPH/MSPH, leads a discussion on long-term monitoring for patients with type 1 diabetes and which providers are most likely to administer and manage teplizumab treatment.

Patient Selection for Teplizumab in T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 13th 2023

Experts in endocrinology share their approach to patient selection for teplizumab in type 1 diabetes and the impact of a 2-year delay in the onset of the disease.

Safety and Efficacy of Teplizumab in T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 13th 2023

Dr Kimberly Simmons reviews key findings from an initial study and extended follow-up on the safety and efficacy of teplizumab in delaying the progression of type 1 diabetes.

New Therapies to Delay T1D Progression

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 8th 2023

Robin S. Goland, MD, and Kimberly Simmons, MD, MPH/MSPH, provide insight on teplizumab, which was recently approved by the FDA, to delay the progression of type 1 diabetes, and they discuss the implications of autoantibody detection in patients.

Delaying Onset of T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 8th 2023

Dr Teresa Quattrin discusses the significance of delaying the onset of type 1 diabetes.

Using Type 2 Diabetes Medications to Treat T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 6th 2023

Teresa Quattrin, MD, leads a discussion on the benefits of using medications for type 2 diabetes to manage patients who have type 1 diabetes.

ADA Guidelines for Managing T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 6th 2023

Kimberly Simmons, MD, MPH/MSPH, reviews ADA guidelines recommendations for the management of type 1 diabetes.

Screening and Diagnosis of T1D

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 3rd 2023

Dr Kimberly Simmons and Dr Teresa Quattrin examine the diagnostic process and importance of screening for type 1 diabetes.

Overview of Type 1 Diabetes (T1D)

ByRobert Busch, MD,Robin S. Goland, MD,Kimberly Simmons, MD,Teresa Quattrin, MD

February 3rd 2023

Robert Busch, MD, and Robin S. Goland, MD, review the prevalence and pathophysiology of type 1 diabetes.

Key Takeaways for Lipid Lowering in Hypercholesterolemia and ASCVD

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky offer key takeaways in the management of hypercholesterolemia and ASCVD.

Barriers and Solutions for Lipid Management in Clinical Practice

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 9th 2022

An expert panel discusses challenges and provides solutions to managing patients with hypercholesterolemia.

Multidisciplinary/Team Based Approach for Lipid Management

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

December 2nd 2022

Our panel highlights the importance of a team-based approach to care in the management of hypercholesterolemia.

Emerging Therapies for Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC

December 2nd 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; provide an overview of upcoming treatment options for managing hypercholesterolemia.

The Role of Combination Therapy in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

Erin D. Michos, MHS, FACC, FASPC; Pam Taub, MD, FACC, FASPC; Robert Busch, MD; Alison Bailey, MD, FACC; and Jorge Plutzky, MD; share benefits of combination therapy for lipid lowering in ASCVD and hypercholesterolemia.

Managing ASCVD in Patients With Statin Intolerance

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 25th 2022

A panel of experts discusses recommendations for managing statin intolerance in patients with hypercholesterolemia.

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Guideline Recommendations for Lipid Lowering

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 18th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

ByErin D. Michos, MD, MHS,Pam Taub, MD, FACC, FASPC,Robert Busch, MD,Alison Bailey, MD, FACC,Jorge Plutzky, MD

November 11th 2022

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.